Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

That overweight person you’re judging might not be able to control the amount they eat. For ten years, Joshua Bell was part ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Watsons Philippines gathered the brilliant names in the health, wellness, and beauty industry for its most anticipated annual ...

The large molecule injectable drugs market is anticipated to expand at a CAGR of ~9% during the forecast period. Key drivers ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.